Literature DB >> 8290467

In vitro evaluation of dexamethasone-beta-D-glucuronide for colon-specific drug delivery.

B Haeberlin1, W Rubas, H W Nolen, D R Friend.   

Abstract

Dexamethasone-beta-D-glucuronide is a potential prodrug for colonic delivery of the antiinflammatory corticosteroid dexamethasone. Previous studies [T. R. Tozer et al., Pharm. Res. 8:445-454 (1991)] indicated that a glucoside prodrug of dexamethasone was susceptible to hydrolysis in the upper gastrointestinal tract. Resistance of dexamethasone-beta-D-glucuronide to hydrolysis in the upper gastrointestinal tract was therefore assessed. Conventional, germfree, and colitic rats were used to examine enzyme levels along the gastrointestinal tract to compare the stability of two model substrates (p-nitrophenyl-beta-D-glucoside and -beta-D-glucuronide) and to evaluate the prodrug dexamethasone-beta-D-glucuronide. Hydrolytic activity was examined in the luminal contents, mucosa, and underlying muscle/connective tissues in all three types of rats. Enzymatic activity (beta-D-glucosidase and beta-D-glucuronidase) was greatest in the lumen of cecum and colon of conventional rats. In contrast, germ-free rats exhibited relatively high levels of beta-D-glucosidase activity (about 80% of total activity in the conventional rats) in the proximal small intestine (PSI) and the distal small intestine (DSI). Rats with induced colitis (acetic acid) showed reduced levels of luminal beta-D-glucuronidase activity in the large intestine; however, beta-D-glucosidase activity was relatively unchanged relative to that of the conventional rat. Mucosal beta-D-glucuronidase activity was significantly lower in the colitic rats compared with that in the conventional animals. Despite reduced luminal levels of beta-D-glucuronidase activity in the colitic rats, there was still a sharp gradient of activity between the small and the large intestines. Permeability of the glucoside and glucuronide prodrugs of dexamethasone through a monolayer of Caco-2 cells was relatively low compared to that of dexamethasone. The results indicate that dexamethasone-beta-D-glucuronide should be relatively stable and poorly absorbed in the upper gastrointestinal tract. Once the compound reaches the large intestine, it should be hydrolyzed to dexamethasone and glucuronic acid. Specificity of colonic delivery in humans should be even greater due to lower levels of beta-D-glucuronidase activity in the small intestine compared with that in the laboratory rat.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8290467     DOI: 10.1023/a:1018956232628

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

1.  Glycosidases in the mammalian alimentary tract.

Authors:  J CONCHIE; D C MACDONALD
Journal:  Nature       Date:  1959-10-17       Impact factor: 49.962

2.  Characterization of the unstirred water layer in Caco-2 cell monolayers using a novel diffusion apparatus.

Authors:  I J Hidalgo; K M Hillgren; G M Grass; R T Borchardt
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

3.  Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats.

Authors:  R N Fedorak; L R Empey; C MacArthur; L D Jewell
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

4.  Faecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease.

Authors:  J M Rhodes; R Gallimore; E Elias; R N Allan; J F Kennedy
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

5.  Origin of intestinal beta-glucuronidase in germfree, monocontaminated and conventional rats.

Authors:  T O Rod; T Midtvedt
Journal:  Acta Pathol Microbiol Scand B       Date:  1977-08

6.  Colonic mucosal lysosomal enzyme activities in ulcerative colitis.

Authors:  S H Danovitch; A Gallucci; W Shora
Journal:  Am J Dig Dis       Date:  1972-11

7.  Comparison of the permeability characteristics of a human colonic epithelial (Caco-2) cell line to colon of rabbit, monkey, and dog intestine and human drug absorption.

Authors:  W Rubas; N Jezyk; G M Grass
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

8.  Response of the small intestinal mucosa to oral glucocorticoids.

Authors:  R M Batt; J Scott
Journal:  Scand J Gastroenterol Suppl       Date:  1982

9.  Effect of ampicillin administration on plasma conjugated and unconjugated estrogen and progesterone levels in pregnancy.

Authors:  H Adlercreutz; F Martin; T Lehtinen; M J Tikkanen; M O Pulkkinen
Journal:  Am J Obstet Gynecol       Date:  1977-06-01       Impact factor: 8.661

10.  LYSOSOMAL ENZYMES OF RAT INTESTINAL MUCOSA.

Authors:  L HSU; A L TAPPEL
Journal:  J Cell Biol       Date:  1964-11       Impact factor: 10.539

View more
  7 in total

Review 1.  Colonic drug delivery: prodrug approach.

Authors:  V R Sinha; R Kumria
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

2.  In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery.

Authors:  C S Leopold; D R Friend
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

Review 3.  Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis.

Authors:  Kazuichi Okazaki; Hiroshi Nakase; Norihiko Watanabe; Yasuhiko Tabata; Yoshito Ikada; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

4.  Menthol-beta-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome.

Authors:  H W Nolen; D R Friend
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

5.  Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease.

Authors:  O Carrette; C Favier; C Mizon; C Neut; A Cortot; J F Colombel; J Mizon
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

Review 6.  Understanding and modulating mammalian-microbial communication for improved human health.

Authors:  Sridhar Mani; Urs A Boelsterli; Matthew R Redinbo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-23       Impact factor: 13.820

7.  Prediction of the permeability of neutral drugs inferred from their solvation properties.

Authors:  Edoardo Milanetti; Domenico Raimondo; Anna Tramontano
Journal:  Bioinformatics       Date:  2015-12-10       Impact factor: 6.937

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.